TLDR
- Q1 adjusted earnings reached $2.65 per share, surpassing analyst expectations of $2.59
- Quarterly revenue climbed to $15 billion, reflecting 12% year-over-year growth and exceeding the $14.72 billion forecast
- Immunology segment posted 16% growth while neuroscience surged 26% during the period
- Company elevated 2026 full-year adjusted EPS guidance to $14.08–$14.28 from previous range of $13.96–$14.16
- Shares climbed 2.5% in premarket sessions, clawing back some of the 13% year-to-date loss
Heading into Wednesday’s quarterly report, AbbVie was nursing a 13% year-to-date decline. The pharmaceutical giant emerged with results that gave shareholders reason for optimism.
The biopharmaceutical company delivered first-quarter adjusted earnings of $2.65 per share, representing growth from $2.46 in the year-ago period and surpassing the Street’s $2.59 expectation. Quarterly revenue reached $15 billion, marking a 12% year-over-year increase and beating analyst projections of $14.72 billion.
Shares of ABBV climbed 2.5% to $202.63 in premarket activity after the announcement.
The revenue outperformance stemmed primarily from strength across two critical business segments. The immunology division expanded 16%, while neuroscience delivered an even more impressive 26% acceleration.
Within immunology, Skyrizi and Rinvoq remained the growth catalysts. Skyrizi, prescribed for arthritis and Crohn’s disease patients, generated 31% revenue expansion during the quarter. Rinvoq contributed 23% growth.
This momentum helped compensate for Humira’s 39% revenue contraction. The former blockbuster therapy faces intensifying pressure from biosimilar alternatives, and its share of the overall portfolio continues its decline.
Management Elevates Full-Year Outlook
AbbVie increased its 2026 full-year adjusted EPS forecast to a band of $14.08 to $14.28, representing an upgrade from the previous $13.96 to $14.16 range. The current Wall Street consensus stands at $14.12, placing the updated midpoint marginally above analyst expectations.
The guidance elevation reflects leadership’s optimism regarding sustained performance from its immunology and neuroscience portfolios.
On a generally accepted accounting principles (GAAP) basis, quarterly net income totaled $695 million, translating to $0.39 per diluted share. This compares with $1.29 billion, or $0.72 per share, during the comparable year-earlier period. The year-over-year GAAP decrease incorporates expenses excluded from adjusted metrics.
Market Context for ABBV Shares
The equity had faced headwinds entering this earnings release, trading 13% below its starting point for the year through Tuesday’s closing bell.
The 2.5% premarket advance indicates market participants responded favorably to both the quarterly beat and enhanced guidance, although the stock remains in recovery mode.
Skyrizi and Rinvoq have emerged as the undisputed growth drivers for AbbVie’s business model, with their combined performance more than compensating for Humira’s persistent decline.
The neuroscience division is establishing itself as an increasingly important revenue pillar. The segment’s 26% expansion rate demonstrates meaningful traction extending beyond the flagship immunology franchise.
AbbVie’s $2.65 adjusted EPS result represented the second straight quarter of year-over-year expansion on this key metric, leaving the prior-year comparison of $2.46 clearly behind.
The company’s enhanced guidance corridor of $14.08 to $14.28 in adjusted earnings per share establishes the benchmark that investors and Wall Street analysts will monitor throughout the remainder of 2026.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
